Ann: Macquarie Australia Conference - Presentation, page-39

The clinical trial website shows that the original anticipated enrolment was 50 patients (15/09/19).

That was changed to 150 patients on 15/09/20 and hasn’t been updated since.

But if you look at Company announcements since the beginning of 2022, it is clear that the target number of patients for enrolment was reduced to 120 and it hasn’t changed since.

According to David Williams, as of 8 April, 98-99 patients had been enrolled.

1H 22 Results 25/02/22
25 US sites and 5 Canadian sites being enrolled, and we expect patient recruitment to increase as more sites are activated. Total trial patients 120.

FY22 Results 26/08/22
Trial is underway with 23 subjects enrolled as of July ‘22 out of a planned 120, across 30 sites (25 in U.S. and 5 in Canada).

J P Morgan Health Conference 11/01/23
Since Jan 2021, a 120 patient Burns Pivotal RCT is underway, in partnership with US FDA and BARDA.

1H FY 23 Results 23/02/23
As at late February 2023, 43 patients have been enrolled into the study out of a target 120.

Macquarie Australia Conference 03/05/23
120 patient Burns Pivotal RCT is underway, in partnership with US FDA and BARDA.

E&P Small Cap Healthcare Conference 12/09/23
Since Jan 2021, a 120 patient Burns Pivotal RCT is underway, in partnership with US FDA and BARDA.

Annual Report 13/09/23
Enrolled 64 patients into the U.S. BARDA pivotal burns study (53%).

BARDA Announcement 02/10/23
To date, 71 patients have been enrolled out of a target 120.

AGM CEO Address 03/11/23
Pivotal trial 76 of 120 enrolled.

Bell Potter Healthcare Conference 15/11/23
Pivotal trial 78 of 120 enrolled.

1HFY24 Results 27/02/24
The Company has passed the mid‑way point for recruitment, with 90 patients enrolled of a target of 120.

Macquarie Australia Conference 08/05/24
120 patient Burns Pivotal RCT is underway and is well-past the mid-way point for recruitment.